Akari Therapeutics (AKTX) Net Cash Flow (2014 - 2026)

Akari Therapeutics has disclosed Net Cash Flow across 9 years of filings, most recently posting -$2.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$2.4 million, down 14223.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $185000.0 (down 80.51% YoY), and the FY2025 annual result was $2.6 million, up 320.22% from the prior year.
• Net Cash Flow came in at -$2.4 million for Q1 2026 at Akari Therapeutics, down from $2.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.9 million in Q2 2024 to a low of -$4.4 million in Q2 2023.
• The 4-year median for Net Cash Flow is -$892000.0 (2023), against an average of -$831384.6.
• Across the five-year window, Net Cash Flow soared 8963.33% in 2025 and slumped 14223.53% in 2026, its largest moves.
• Akari Therapeutics' Net Cash Flow stood at -$892000.0 in 2023, then surged by 103.36% to $30000.0 in 2024, then jumped by 8963.33% to $2.7 million in 2025, then slumped by 189.55% to -$2.4 million in 2026.
• The last three Net Cash Flow figures came in at -$2.4 million (Q1 2026), $2.7 million (Q4 2025), and -$224000.0 (Q3 2025), per Business Quant data.